Scotiabank raised the firm’s price target on Rocket Pharmaceuticals (RCKT) to $52 from $51 and keeps an Outperform rating on the shares. The company is on track to report preliminary data from phase 1 study on RP-A601 in patients with Plakophilin-2 arrhythmogenic cardiomyopathy, which the firm expects will be a high impact catalyst, the analyst tells investors. Additionally, the firm expects the launch of Kresladi later this year and forecasts market entry of RP-L 102 in 2026.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Rocket Pharmaceuticals price target lowered to $36 from $39 at Canaccord
- Promising Pipeline and Financial Stability Drive Buy Rating for Rocket Pharmaceuticals
- Rocket Pharmaceuticals Advances Gene Therapy Pipeline
- Rocket Pharmaceuticals price target lowered to $15 from $29 at Goldman Sachs
- Rocket Pharmaceuticals price target lowered to $54 from $62 at Chardan